Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.


Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.

Keywords: HIV-1; bNAb; broadly neutralizing antibody; prevention; vaccine; viral diversity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Neutralizing / immunology*
  • Clinical Trials as Topic
  • Disease Management
  • Genetic Variation
  • HIV Antibodies / immunology*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Host-Pathogen Interactions / immunology*
  • Humans
  • Immunization, Passive
  • RNA, Viral
  • Structure-Activity Relationship
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Viral Proteins / chemistry
  • Viral Proteins / genetics


  • AIDS Vaccines
  • Antibodies, Neutralizing
  • HIV Antibodies
  • RNA, Viral
  • Viral Proteins